## Shlomo Keidar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11765513/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Vitamin E Supplementation Reduces Cardiovascular Events in a Subgroup of Middle-Aged Individuals With Both Type 2 Diabetes Mellitus and the Haptoglobin 2-2 Genotype. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 341-347.	2.4	263
2	Aldosterone Administration to Mice Stimulates Macrophage NADPH Oxidase and Increases Atherosclerosis Development. Circulation, 2004, 109, 2213-2220.	1.6	242
3	ACE2 of the heart: From angiotensin I to angiotensin (1–7). Cardiovascular Research, 2007, 73, 463-469.	3.8	220
4	Mineralocorticoid Receptor Blocker Increases Angiotensin-Converting Enzyme 2 Activity in Congestive Heart Failure Patients. Circulation Research, 2005, 97, 946-953.	4.5	187
5	Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis, 1997, 128, 11-18.	0.8	179
6	Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis, 1995, 115, 201-215.	0.8	148
7	The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovascular Research, 1999, 44, 579-587.	3.8	137
8	The Angiotensin-II Receptor Antagonist, Losartan, Inhibits LDL Lipid Peroxidation and Atherosclerosis in Apolipoprotein E-Deficient Mice. Biochemical and Biophysical Research Communications, 1997, 236, 622-625.	2.1	129
9	Effect of Eplerenone, a Selective Aldosterone Blocker, on Blood Pressure, Serum and Macrophage Oxidative Stress, and Atherosclerosis in Apolipoprotein E–Deficient Mice. Journal of Cardiovascular Pharmacology, 2003, 41, 955-963.	1.9	123
10	Angiotensin II Administration to Atherosclerotic Mice Increases Macrophage Uptake of Oxidized LDL. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1464-1469.	2.4	110
11	Interactions of Platelets, Macrophages, and Lipoproteins in Hypercholesterolemia: Antiatherogenic Effects of HMG-CoA Reductase Inhibitor Therapy. Journal of Cardiovascular Pharmacology, 1998, 31, 39-45.	1.9	109
12	Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: a possible role for angiotensin II. Atherosclerosis, 1994, 107, 71-84.	0.8	103
13	Antiatherosclerotic and Antioxidative Effects of Captopril in Apolipoprotein E-Deficient Mice. Journal of Cardiovascular Pharmacology, 1998, 31, 540-544.	1.9	100
14	Angiotensin II atherogenicity in apolipoprotein E deficient mice is associated with increased cellular cholesterol biosynthesis. Atherosclerosis, 1999, 146, 249-257.	0.8	95
15	A mouse model for human atherosclerosis: Long-term histopathological study of lesion development in the aortic arch of apolipoprotein E-deficient (E0) mice. Acta Histochemica, 2006, 108, 415-424.	1.8	87
16	Angiotensin, LDL peroxidation and atherosclerosis. Life Sciences, 1998, 63, 1-11.	4.3	81
17	Angiotensin II–Modified LDL Is Taken Up by Macrophages Via the Scavenger Receptor, Leading to Cellular Cholesterol Accumulation. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 97-105.	2.4	69
18	Increased Uptake of LDL by Oxidized Macrophages is the Result of an Initial Enhanced LDL Receptor Activity and of a Further Progressive Oxidation of LDL. Free Radical Biology and Medicine, 1997, 23, 34-46.	2.9	64

Shlomo Keidar

#	Article	IF	CITATIONS
19	Apolipoprotein E and its role in aging and survival. Experimental Gerontology, 2010, 45, 149-157.	2.8	61
20	Attenuation of Atherosclerosis in Apolipoprotein E-Deficient Mice by Ramipril is Dissociated from Its Antihypertensive Effect and from Potentiation of Bradykinin. Journal of Cardiovascular Pharmacology, 2000, 35, 64-72.	1.9	58
21	Macrophage-foam cell formation in streptozotocin-induced diabetic mice: Stimulatory effect of glucose. Atherosclerosis, 2005, 183, 25-33.	0.8	56
22	ACE2 activity is increased in monocyte-derived macrophages from prehypertensive subjects. Nephrology Dialysis Transplantation, 2006, 22, 597-601.	0.7	51
23	Ramipril administration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis. Atherosclerosis, 2002, 161, 65-74.	0.8	43
24	Angiotensin II Injection into Mice Increases the Uptake of Oxidized LDL by Their Macrophages via a Proteoglycan-Mediated Pathway. Biochemical and Biophysical Research Communications, 1997, 239, 63-67.	2.1	41
25	Fosinopril Reduces ADP-Induced Platelet Aggregation in Hypertensive Patients. Journal of Cardiovascular Pharmacology, 1996, 27, 183-186.	1.9	34
26	Tissue Angiotensin-Converting-Enzyme (ACE) Deficiency Leads to a Reduction in Oxidative Stress and in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 2090-2096.	2.4	33
27	Losartan Inhibits Cellular Uptake of Oxidized LDL by Monocyte-Macrophages from Hypercholesterolemic Patients. Biochemical and Biophysical Research Communications, 2000, 273, 417-420.	2.1	32
28	Apolipoprotein E and lipoprotein lipase reduce macrophage degradation of oxidized very-low-density lipoprotein (VLDL), but increase cellular degradation of native VLDL. Metabolism: Clinical and Experimental, 1992, 41, 1185-1192.	3.4	26
29	ENDOGENOUS CORTISOL AND THYROID HORMONE LEVELS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION. Clinical Endocrinology, 1983, 19, 131-139.	2.4	25
30	Angiotensin II Reduces Macrophage Cholesterol Efflux: A Role for the AT-1 Receptor but Not for the ABC1 Transporter. Biochemical and Biophysical Research Communications, 2002, 290, 1529-1534.	2.1	25
31	Dual Therapy With Statins and Antioxidants Is Superior to Statins Alone in Decreasing the Risk of Cardiovascular Disease in a Subgroup of Middle-Aged Individuals With Both Diabetes Mellitus and the Haptoglobin 2-2 Genotype. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, e18-20.	2.4	25
32	Eplerenone Reduced Lesion Size in Early but Not Advanced Atherosclerosis in Apolipoprotein E–Deficient Mice. Journal of Cardiovascular Pharmacology, 2012, 60, 508-512.	1.9	25
33	FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice. Journal of Hypertension, 2010, 28, 1900-1907.	0.5	23
34	Angiotensin II increases the expression of lectin-like oxidized low-density lipoprotein receptor-1 in human vascular smooth muscle cells via a lipoxygenase-dependent pathway. American Journal of Hypertension, 2005, 18, 299-307.	2.0	22
35	Mineralocorticoid receptor blockade inhibits accelerated atherosclerosis induced by a low sodium diet in apolipoprotein E-deficient mice. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2014, 15, 228-235.	1.7	21
36	High plasma high-density lipoprotein levels, very low cardiovascular risk profile, and subclinical carotid atherosclerosis in postmenopausal women. Journal of Clinical Lipidology, 2009, 3, 345-350.	1.5	17

Shlomo Keidar

#	Article	IF	CITATIONS
37	Paraoxonase1 deficiency in mice is associated with hypotension and increased levels of 5,6-epoxyeicosatrienoic acid. Atherosclerosis, 2012, 222, 92-98.	0.8	17
38	Transient Right to Left Atrial Shunt Detected by Contrast Echocardiography in the Acute Stage of Pulmonary Embolism. Journal of Clinical Ultrasound, 1984, 12, 417-419.	0.8	16
39	A high carbohydrate-fat free diet alters the proportion of heparin-bound VLDL in plasma and the expression of VLDL-apoB-100 epitopes. Metabolism: Clinical and Experimental, 1990, 39, 281-288.	3.4	16
40	Oxidative stress increases the expression of the angiotensin-II receptor type 1 in mouse peritoneal macrophages. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2002, 3, 24-30.	1.7	16
41	Omapatrilat Decreased Macrophage Oxidative Status and Atherosclerosis Progression in Atherosclerotic Apolipoprotein E-Deficient Mice. Journal of Cardiovascular Pharmacology, 2004, 43, 140-147.	1.9	16
42	Atherosclerosis and the protective role played by different proteins in apolipoprotein E-deficient mice. Acta Histochemica, 2007, 109, 45-51.	1.8	16
43	Aldosterone upâ€regulates 12―and 15â€lipoxygenase expression and LDL oxidation in human vascular smooth muscle cells. Journal of Cellular Biochemistry, 2009, 108, 1203-1210.	2.6	16
44	Paraoxonase 1 deficiency in mice is associated with reduced steroid biosynthesis: Effects on HDL binding, cholesteryl ester accumulation and scavenger receptor type BI expression. Atherosclerosis, 2010, 211, 130-135.	0.8	6
45	Atherosclerosis: The Apolipoprotein E-Deficient Mouse Model Revisited. Microscopy and Microanalysis, 2002, 8, 944-945.	0.4	0